Skip to content
Screener

Supernus Pharmaceuticals SUPN G&A

G&A at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$23.93M+24.4%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$11.37M+81.5%

Segments

By segment

See full
Reportable Segment$38.2M+43.2%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+21.8%
Enterprise value$2.63B+21.5%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

FAQ

What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.